<?xml version="1.0" encoding="UTF-8"?>
<p id="Par1502">
 <bold>Introductions:</bold> Colistin, a last-line therapeutic agent for the treatment of multidrug-resistance gram-negative infections, is limited in its use due to nephrotoxicity. This retrospective cohort study evaluates risk factors for colistin-induced severe acute kidney injury (AKI) in critically ill patients.
</p>
